GCP
PEAR

GSA Capital Partners’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

GSA Capital Partners’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28,900
Closed -$146K – 1938
2022
Q1 		$146K Buy
+28,900
New +$131K 0.02% 1237

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's PEAR Position: Q2 2022 in Review

GSA Capital Partners sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 28,900 shares — an estimated $146K sold.

GSA Capital Partners first reported a position in PEAR in Q1 2022 and held it in 1 quarter. The position peaked at $146K in Q1 2022. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

  • GSA Capital Partners reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • GSA Capital Partners sold 28,900 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022, an estimated $146K.
  • GSA Capital Partners first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 1 quarter.
  • GSA Capital Partners's Pear Therapeutics, Inc. Class A Common Stock position peaked at $146K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.